AKT1 and lung cancer: The study showed that fisetin efficiently enhanced the sensitivity of erlotinib-resistant lung cancer cells to erlotinib, probably via preventing the abnormal activation of AKT as well as MAPK signaling pathways brought about from the suppression of AXL.